{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:39:02Z","timestamp":1792438742604,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81819-8","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T02:31:35Z","timestamp":1735353095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with Down syndrome regression disorder"],"prefix":"10.1038","volume":"14","author":[{"given":"Jonathan D.","family":"Santoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Jafarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Keehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellad M.","family":"Khoshnood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Kazerooni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie K.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin N.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Nagesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi A.","family":"Spinazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Besterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen A.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Rafii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"81819_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/ajmg.a.37001","volume":"167a","author":"G de Graaf","year":"2015","unstructured":"de Graaf, G., Buckley, F. & Skotko, B. G. Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. Am. J. Med. Genet. A. 167a, 756\u2013767. https:\/\/doi.org\/10.1002\/ajmg.a.37001 (2015).","journal-title":"Am. J. Med. Genet. A"},{"key":"81819_CR2","doi-asserted-by":"publisher","unstructured":"Mircher, C. et al. Acute regression in young people with Down syndrome. Brain Sci. 7 https:\/\/doi.org\/10.3390\/brainsci7060057 (2017).","DOI":"10.3390\/brainsci7060057"},{"key":"81819_CR3","doi-asserted-by":"publisher","unstructured":"Rosso, M. et al. Down syndrome disintegrative disorder: A clinical regression syndrome of increasing importance. Pediatrics 145 https:\/\/doi.org\/10.1542\/peds.2019-2939 (2020).","DOI":"10.1542\/peds.2019-2939"},{"key":"81819_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1177\/0883073814554654","volume":"30","author":"G Worley","year":"2015","unstructured":"Worley, G. et al. Down syndrome disintegrative disorder: New-onset autistic regression, dementia, and insomnia in older children and adolescents with Down syndrome. J. Child. Neurol. 30, 1147\u20131152. https:\/\/doi.org\/10.1177\/0883073814554654 (2015).","journal-title":"J. Child. Neurol."},{"key":"81819_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/ndt.S77307","volume":"11","author":"N Ghaziuddin","year":"2015","unstructured":"Ghaziuddin, N., Nassiri, A. & Miles, J. H. Catatonia in Down syndrome; A treatable cause of regression. Neuropsychiatr. Dis. Treat. 11, 941\u2013949. https:\/\/doi.org\/10.2147\/ndt.S77307 (2015).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"81819_CR6","doi-asserted-by":"publisher","unstructured":"Santoro, J. D. et al. Evidence of neuroinflammation and immunotherapy responsiveness in individuals with Down syndrome regression disorder. J. Neurodev Disord. 14 https:\/\/doi.org\/10.1186\/s11689-022-09446-w (2022).","DOI":"10.1186\/s11689-022-09446-w"},{"key":"81819_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.62922","author":"SL Santoro","year":"2022","unstructured":"Santoro, S. L. et al. Unexplained regression in Down syndrome: Management of 51 patients in an international patient database. Am. J. Med. Genet. A. https:\/\/doi.org\/10.1002\/ajmg.a.62922 (2022).","journal-title":"Am. J. Med. Genet. A"},{"key":"81819_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41436-019-0706-8","volume":"22","author":"SL Santoro","year":"2020","unstructured":"Santoro, S. L. et al. Unexplained regression in Down syndrome: 35 cases from an international Down syndrome database. Genet. Med. 22, 767\u2013776. https:\/\/doi.org\/10.1038\/s41436-019-0706-8 (2020).","journal-title":"Genet. Med."},{"key":"81819_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-023-06057-9","author":"JD Santoro","year":"2023","unstructured":"Santoro, J. D. et al. Alternative diagnoses in the work up of Down syndrome regression disorder. J. Autism Dev. Disord. https:\/\/doi.org\/10.1007\/s10803-023-06057-9 (2023).","journal-title":"J. Autism Dev. Disord"},{"key":"81819_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.17294\/2330-0698.1875","volume":"9","author":"A Rivelli","year":"2022","unstructured":"Rivelli, A. et al. Prevalence of mental health conditions among 6078 individuals with Down syndrome in the United States. J. Patient Cent. Res. Rev. 9, 58\u201363. https:\/\/doi.org\/10.17294\/2330-0698.1875 (2022).","journal-title":"J. Patient Cent. Res. Rev."},{"key":"81819_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.17294\/2330-0698.1824","volume":"8","author":"B Chicoine","year":"2021","unstructured":"Chicoine, B. et al. Prevalence of common disease conditions in a large cohort of individuals with Down syndrome in the United States. J. Patient Cent. Res. Rev. 8, 86\u201397. https:\/\/doi.org\/10.17294\/2330-0698.1824 (2021).","journal-title":"J. Patient Cent. Res. Rev."},{"key":"81819_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41398-023-02579-z","volume":"13","author":"JD Santoro","year":"2023","unstructured":"Santoro, J. D. et al. Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder. Transl. Psychiatry. 13, 276. https:\/\/doi.org\/10.1038\/s41398-023-02579-z (2023).","journal-title":"Transl. Psychiatry"},{"key":"81819_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/dmcn.14127","volume":"61","author":"KM Cardinale","year":"2019","unstructured":"Cardinale, K. M. et al. Immunotherapy in selected patients with Down syndrome disintegrative disorder. Dev. Med. Child. Neurol. 61, 847\u2013851. https:\/\/doi.org\/10.1111\/dmcn.14127 (2019).","journal-title":"Dev. Med. Child. Neurol."},{"key":"81819_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41586-023-05736-y","volume":"615","author":"L Malle","year":"2023","unstructured":"Malle, L. et al. Autoimmunity in Down\u2019s syndrome via cytokines, CD4 T cells and CD11c(+) B cells. Nature 615, 305\u2013314. https:\/\/doi.org\/10.1038\/s41586-023-05736-y (2023).","journal-title":"Nature"},{"key":"81819_CR15","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.celrep.2019.10.038","volume":"29","author":"KA Waugh","year":"2019","unstructured":"Waugh, K. A. et al. Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in Down syndrome. Cell. Rep. 29, 1893\u20131908e1894. https:\/\/doi.org\/10.1016\/j.celrep.2019.10.038 (2019).","journal-title":"Cell. Rep."},{"key":"81819_CR16","doi-asserted-by":"publisher","first-page":"24231","DOI":"10.1073\/pnas.1908129116","volume":"116","author":"P Araya","year":"2019","unstructured":"Araya, P. et al. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proc. Natl. Acad. Sci. U S A. 116, 24231\u201324241. https:\/\/doi.org\/10.1073\/pnas.1908129116 (2019).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"81819_CR17","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1093\/rheumatology\/keab203","volume":"60","author":"AT Pham","year":"2021","unstructured":"Pham, A. T. et al. JAK inhibition for treatment of psoriatic arthritis in Down syndrome. Rheumatology (Oxford) 60, e309\u2013e311. https:\/\/doi.org\/10.1093\/rheumatology\/keab203 (2021).","journal-title":"Rheumatology (Oxford)"},{"key":"81819_CR18","doi-asserted-by":"publisher","first-page":"14818","DOI":"10.1038\/s41598-017-13858-3","volume":"7","author":"KD Sullivan","year":"2017","unstructured":"Sullivan, K. D. et al. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Sci. Rep. 7, 14818. https:\/\/doi.org\/10.1038\/s41598-017-13858-3 (2017).","journal-title":"Sci. Rep."},{"key":"81819_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/jir.12804","volume":"65","author":"D Valentini","year":"2021","unstructured":"Valentini, D. et al. Medical conditions of children and young people with Down syndrome. J. Intellect. Disabil. Res. 65, 199\u2013209. https:\/\/doi.org\/10.1111\/jir.12804 (2021).","journal-title":"J. Intellect. Disabil. Res."},{"key":"81819_CR20","doi-asserted-by":"publisher","unstructured":"Sullivan, K. D. et al. Trisomy 21 consistently activates the interferon response. Elife 5 https:\/\/doi.org\/10.7554\/eLife.16220 (2016).","DOI":"10.7554\/eLife.16220"},{"key":"81819_CR21","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1172\/jci129301","volume":"130","author":"AA de Jesus","year":"2020","unstructured":"de Jesus, A. A. et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J. Clin. Invest. 130, 1669\u20131682. https:\/\/doi.org\/10.1172\/jci129301 (2020).","journal-title":"J. Clin. Invest."},{"key":"81819_CR22","doi-asserted-by":"publisher","first-page":"724436","DOI":"10.3389\/fimmu.2022.724436","volume":"13","author":"D Peeters","year":"2022","unstructured":"Peeters, D. et al. AKT hyperphosphorylation and T cell exhaustion in Down syndrome. Front. Immunol. 13, 724436. https:\/\/doi.org\/10.3389\/fimmu.2022.724436 (2022).","journal-title":"Front. Immunol."},{"key":"81819_CR23","doi-asserted-by":"publisher","first-page":"724969","DOI":"10.3389\/fneur.2021.724969","volume":"12","author":"JD Santoro","year":"2021","unstructured":"Santoro, J. D. et al. Increased autoimmunity in individuals with Down syndrome and Moyamoya disease. Front. Neurol. 12, 724969. https:\/\/doi.org\/10.3389\/fneur.2021.724969 (2021).","journal-title":"Front. Neurol."},{"key":"81819_CR24","doi-asserted-by":"publisher","unstructured":"Lai, F., Mercaldo, N., Wang, C. M., Hersch, G. G. & Rosas, H. D. Association between inflammatory conditions and Alzheimer\u2019s disease age of onset in Down syndrome. J. Clin. Med. 10 https:\/\/doi.org\/10.3390\/jcm10143116 (2021).","DOI":"10.3390\/jcm10143116"},{"key":"81819_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1530\/eje-19-0823","volume":"182","author":"G Pepe","year":"2020","unstructured":"Pepe, G. et al. Prospective evaluation of autoimmune and non-autoimmune subclinical hypothyroidism in Down syndrome children. Eur. J. Endocrinol. 182, 385\u2013392. https:\/\/doi.org\/10.1530\/eje-19-0823 (2020).","journal-title":"Eur. J. Endocrinol."},{"key":"81819_CR26","doi-asserted-by":"publisher","unstructured":"Ludvigsson, J. F., Lebwohl, B., Green, P. H., Chung, W. K. & M\u00e5rild, K. Celiac disease and Down syndrome mortality: A nationwide cohort study. BMC Pediatr. 17 https:\/\/doi.org\/10.1186\/s12887-017-0801-4 (2017).","DOI":"10.1186\/s12887-017-0801-4"},{"key":"81819_CR27","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/0009922820941247","volume":"59","author":"KK Ostermaier","year":"2020","unstructured":"Ostermaier, K. K. et al. Incidence of celiac disease in Down syndrome: A longitudinal, population-based birth cohort study. Clin. Pediatr. (Phila). 59, 1086\u20131091. https:\/\/doi.org\/10.1177\/0009922820941247 (2020).","journal-title":"Clin. Pediatr. (Phila)"},{"key":"81819_CR28","doi-asserted-by":"crossref","unstructured":"Anwar, A. J., Walker, J. D. & Frier, B. M. Type 1 diabetes mellitus and Down\u2019s syndrome: Prevalence, management and diabetic complications. Diabet. Med. 15, 160\u2013163. https:\/\/doi.org\/10.1002\/(sici)1096-9136(199802)15:2<160::Aid-dia537>3.0.Co;2-j (1998).","DOI":"10.1002\/(SICI)1096-9136(199802)15:2<160::AID-DIA537>3.0.CO;2-J"},{"key":"81819_CR29","doi-asserted-by":"publisher","first-page":"562","DOI":"10.20945\/2359-3997000000365","volume":"65","author":"DMF Pessoa","year":"2021","unstructured":"Pessoa, D. M. F. et al. Characteristics of type 1 diabetes mellitus in children and adolescents with Down\u2019s syndrome in an admixed population. Arch. Endocrinol. Metab. 65, 562\u2013569. https:\/\/doi.org\/10.20945\/2359-3997000000365 (2021).","journal-title":"Arch. Endocrinol. Metab."},{"key":"81819_CR30","first-page":"191","volume":"48","author":"MH Chen","year":"2007","unstructured":"Chen, M. H., Chen, S. J., Su, L. Y. & Yang, W. Thyroid dysfunction in patients with Down syndrome. Acta Paediatr. Taiwan. 48, 191\u2013195 (2007).","journal-title":"Acta Paediatr. Taiwan."},{"key":"81819_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1440-1754.2007.01229.x","volume":"44","author":"R da Utiyama","year":"2008","unstructured":"da Utiyama, R. Autoantibodies in patients with Down syndrome: Early senescence of the immune system or precocious markers for immunological diseases? J. Paediatr. Child. Health. 44, 182\u2013186. https:\/\/doi.org\/10.1111\/j.1440-1754.2007.01229.x (2008).","journal-title":"J. Paediatr. Child. Health"},{"key":"81819_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/jnnp-2022-330237","volume":"94","author":"M Gastaldi","year":"2023","unstructured":"Gastaldi, M. et al. Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: A multicentre retrospective study. J. Neurol. Neurosurg. Psychiatry. 94, 201\u2013210. https:\/\/doi.org\/10.1136\/jnnp-2022-330237 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"81819_CR33","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/ene.14631","volume":"28","author":"S Macher","year":"2021","unstructured":"Macher, S. et al. Longitudinal measurement of cerebrospinal fluid neurofilament light in anti-N-methyl-D-aspartate receptor encephalitis. Eur. J. Neurol. 28, 1401\u20131405. https:\/\/doi.org\/10.1111\/ene.14631 (2021).","journal-title":"Eur. J. Neurol."},{"key":"81819_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/1550059416677398","volume":"48","author":"Y Shi","year":"2017","unstructured":"Shi, Y. Serial EEG monitoring in a patient with anti-NMDA receptor encephalitis. Clin. EEG Neurosci. 48, 301\u2013303. https:\/\/doi.org\/10.1177\/1550059416677398 (2017).","journal-title":"Clin. EEG Neurosci."},{"key":"81819_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.clinph.2018.10.017","volume":"130","author":"S Jeannin-Mayer","year":"2019","unstructured":"Jeannin-Mayer, S. et al. EEG analysis in anti-NMDA receptor encephalitis: Description of typical patterns. Clin. Neurophysiol. 130, 289\u2013296. https:\/\/doi.org\/10.1016\/j.clinph.2018.10.017 (2019).","journal-title":"Clin. Neurophysiol."},{"key":"81819_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.pediatrneurol.2017.09.002","volume":"78","author":"F Al Mutairi","year":"2018","unstructured":"Al Mutairi, F. et al. Phenotypic and molecular spectrum of Aicardi-Gouti\u00e8res syndrome: A study of 24 patients. Pediatr. Neurol. 78, 35\u201340. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.09.002 (2018).","journal-title":"Pediatr. Neurol."},{"key":"81819_CR37","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1055\/s-0037-1601449","volume":"48","author":"GI Rice","year":"2017","unstructured":"Rice, G. I. et al. Genetic, phenotypic, and interferon biomarker status in ADAR1-related neurological disease. Neuropediatrics 48, 166\u2013184. https:\/\/doi.org\/10.1055\/s-0037-1601449 (2017).","journal-title":"Neuropediatrics"},{"key":"81819_CR38","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1136\/annrheumdis-2014-205396","volume":"74","author":"E Cuadrado","year":"2015","unstructured":"Cuadrado, E. et al. Aicardi-Gouti\u00e8res syndrome harbours abundant systemic and brain-reactive autoantibodies. Ann. Rheum. Dis. 74, 1931\u20131939. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205396 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"81819_CR39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1212\/WNL.0b013e3182872694","volume":"80","author":"A Takanohashi","year":"2013","unstructured":"Takanohashi, A. et al. Elevation of proinflammatory cytokines in patients with Aicardi-Gouti\u00e8res syndrome. Neurology 80, 997\u20131002. https:\/\/doi.org\/10.1212\/WNL.0b013e3182872694 (2013).","journal-title":"Neurology"},{"key":"81819_CR40","doi-asserted-by":"publisher","first-page":"577324","DOI":"10.1016\/j.jneuroim.2020.577324","volume":"347","author":"G Culler","year":"2020","unstructured":"Culler, G., Bachman, E. & VanHaerents, S. Paraclinical serum markers as aids in the diagnosis of autoimmune encephalitis. J. Neuroimmunol. 347, 577324. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577324 (2020).","journal-title":"J. Neuroimmunol."},{"key":"81819_CR41","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/jnnp-2012-303807","volume":"84","author":"Y Hacohen","year":"2013","unstructured":"Hacohen, Y. et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J. Neurol. Neurosurg. Psychiatry. 84, 748\u2013755. https:\/\/doi.org\/10.1136\/jnnp-2012-303807 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"81819_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","volume":"11","author":"JD L\u00fcnemann","year":"2015","unstructured":"L\u00fcnemann, J. D., Nimmerjahn, F. & Dalakas, M. C. Intravenous immunoglobulin in neurology\u2013mode of action and clinical efficacy. Nat. Rev. Neurol. 11, 80\u201389. https:\/\/doi.org\/10.1038\/nrneurol.2014.253 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"81819_CR43","doi-asserted-by":"publisher","first-page":"940175","DOI":"10.3389\/fneur.2022.940175","volume":"13","author":"JD Santoro","year":"2022","unstructured":"Santoro, J. D. et al. Assessment and diagnosis of Down syndrome regression disorder: International Expert Consensus. Front. Neurol. 13, 940175. https:\/\/doi.org\/10.3389\/fneur.2022.940175 (2022).","journal-title":"Front. Neurol."},{"key":"81819_CR44","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Ed. (2013).","DOI":"10.1176\/appi.books.9780890425596"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81819-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81819-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81819-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T16:04:43Z","timestamp":1735401883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81819-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["81819"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81819-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Santoro receives research support from the National Institutes of Health and consulting fees from UCB, TG pharmaceuticals and Cycle Pharmaceuticals. Dr. Rafii has received grants or contracts from Eisai (AHEAD Study) and Eli Lilly (A4 Study), which were paid to his institution. He has received consulting fees from AC Immune, Corium and Ionis. He has participated on a Data Safety Monitoring Board or Advisory Board for Alzheon, Aptah Bio, Biohaven, Embic, Keystone Bio and Positrigo. All other authors reported no biomedical financial interests or potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"<i>Cerebrospinal fluid (CSF)<\/i>,<i> electroencephalogram (EEG)<\/i>,<i> magnetic resonance imaging (MRI)<\/i>.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Legend"}}],"article-number":"30865"}}